Earnings Call · Q2 FY2022·2022-07-29

Q2 22EPS -29.27%·Rev n/aQ1 22EPS -15.73%·Rev n/aQ4 21EPS -30.25%·Rev n/aQ3 21EPS -31.82%·Rev n/a⚠ consensus missing

Ultragenyx Pharmaceutical Inc. RARE

Joshua Higa — Investor Relations

Emil Kakkis — Chief Executive Officer and President

+2.7%1d on move date+1.2% vs SPY3d−1.2%5d+7.5%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RARE calls or request research access.

More RARE calls Browse calls Request research access